Establishes U.S. Clinical Advisory Board
Announces Plans to Open U.S. Office
Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company whose purpose is to develop new therapies for unmet medical needs in the field of cardiovascular diseases, today announced the establishment of a U.S. Clinical Advisory Board of renowned cardiologists and cardiovascular researchers. The members will provide clinical and strategic guidance to the Company on the design of its hypertension clinical trial in the U.S. for lead product candidate QGC001, planned for 2017. Additionally, this newly-formed Clinical Advisory Board will work with the Scientific Advisory Board members to raise visibility of the Company's novel class of centrally-acting drugs called Brain Aminopeptidase A Inhibitors (BAPAIs) for the treatment of high blood pressure and the prevention of related cardiovascular risks such as heart failure.
The initial appointments to Quantum Genomics' Clinical Advisory Board include:
- Keith Ferdinand, MD — Professor of Medicine at the Tulane University School of Medicine;
- Henry Black, MD — Adjunct Clinical Professor of Medicine and member of the Section of Cardiology at the New York University School of Medicine, New York;
- Howard Dittrich, MD — Adjunct Professor of Medicine at the University of Iowa Carver College of Medicine and Chairman of the Board of Directors of the François M. Abboud Cardiovascular Research Center at the University of Iowa Carver College of Medicine.
Additionally, the Company announced its intention to establish a new office in New York City to advance its clinical programs and expand its presence in the United States. The launch of this New York office is expected to help strengthen Quantum Genomics' development activities in the U.S. and enable the Company to more effectively engage with members of the U.S. medical and investment communities.
Lionel Ségard, President and CEO of Quantum Genomics, commented,
“We are honored to welcome such distinguished and experienced clinicians and thought leaders to the Quantum Genomics team. Together we share a common goal of bringing new therapeutic treatments to hypertension patients who currently have few effective options. Dr. Ferdinand, Dr. Black and Dr. Dittrich bring invaluable expertise in the fields of hypertension and cardiology, including translational work and clinical trial design that will be critical to designing and implementing effectively-powered trials for these particular patient populations. We will work closely with them to further advance our BAPAI technology and family of therapeutic candidates, and look forward to their contributions to the continued development of our assets and design of our planned clinical trials.”
Mr. Ségard continued, “Furthermore, the establishment of an office in the U.S. will be instrumental to partnering with our newly-formed Clinical Advisory Board to effectively plan and advance our clinical trial programs, enhance our business strategy and alignment with the U.S. regulators, as well as continue and develop our relationships with the U.S. financial community and the pharmaceutical industry.”
Keith C Ferdinand, MD, is Professor of Medicine at the Tulane University School of Medicine in New Orleans, Louisiana. He is board-certified in internal medicine and cardiovascular disease, certified in the subspecialty of nuclear cardiology, and a specialist in clinical hypertension certified by the American Society of Hypertension. Dr. Ferdinand is Immediate Past Chair of the National Forum for Heart Disease and Stroke Prevention. As an investigator, Dr. Ferdinand has conducted numerous trials and widely published in the fields of cardiology, cardiovascular disease, hypertension, lipids and cardio metabolic risk, especially in racial and ethnic minorities. In 2015, he was the Editor of the book, “Hypertension in High Risk African Americans”, published by Springer. In 2004, Dr. Ferdinand received the Louis B. Russell, Jr. Memorial Award of the American Heart Association and in 2010, the Walter M. Booker Community Service Award of the Association of Black Cardiologists, of which he is past Chair and Chief Science Officer. He has been recognized by the Congressional Black Caucus Health Trust with an award for journalism, as well as the Charles Drew award for medical excellence in conjunction with the National Minority Quality Foundation. In 2015, Dr. Ferdinand was inducted into the Association of University Cardiologists.
Dr. Henry Black is currently a member of the International Society of Hypertension and was a former President of the American Society of Hypertension. He has held faculty positions at Yale and Rush University. Dr. Black also served as a member of the Food and Drug Administration CardioRenal Advisory Committee. Dr. Black has participated in and been in a leadership role in several landmark clinical trials including the Systolic Hypertension in the Elderly Program (SHEP), the Antihypertensive and Lipid Lower Trial to Prevent Heart Attack (ALLHAT), CONVINCE, and the Women's Health Initiative (WHI). He has published more than 400 papers, chapters and reviews and is an author or co-author on more than 220 abstracts. Dr. Black holds an A.B. degree from the Columbia University and an M.D. from the New York University School of Medicine. He completed his residency in internal medicine at Johns Hopkins University and Yale University.
Dr. Howard Dittrich currently serves as an Entrepreneur-in-Residence for Frazier Healthcare Partners, Chief Medical Officer of Hawkeye Therapeutics (a Frazier Healthcare financed “searchco”), and consulting Chief Medical Officer at Leading Biosciences. He is a cardiologist with more than 20 years of experience in cardiovascular research and clinical development. In addition, Dr. Dittrich co-founded and serves as Chairman of the board of directors of IOWA Approach Inc., privately-held company developing atrial fibrillation ablation technology, and President and Board member of Advanced Endovascular Therapeutics, an early stage device company focused on novel coating technology for endovascular devices. He also serves as director for Mast Therapeutics, Inc., a US public biotechnology company. Previously, Dr. Dittrich held executive positions overseeing clinical development and regulatory affairs at Sorbent Therapeutics, NovaCardia, Inc, and Molecular Biosystems, Inc. and Alliance Pharmaceutical Corp., during which time he was involved in gaining U.S. FDA approval for two cardiovascular imaging agents. He held a faculty position at University of California San Diego (UCSD) in the Department of Medicine and Division of Cardiology. Dr. Dittrich holds a B.S. degree from the University of Iowa and an M.D. from the University Of Iowa Carver College Of Medicine. He completed his residency in internal medicine and clinical fellowship in cardiology at UCSD.
Chairman & Chief Executive Officer
+33 1 85 34 77 77
CFO – Investor Relations
+33 1 85 34 77 75
ACTUS finance et communication
+33 1 53 67 36 73
The Ruth Group (U.S.) Lee Roth / Kirsten Thomas
Investor / Public Relations
+1 646-536-7012 / +1 508-280-6592
|ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
Twitter: @ALQGC - LinkedIn: Quantum Genomics
Communiqués au titre de l'obligation d'information permanente :
- Autres communiqués
Full and original press release in PDF:
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|QUANTUM GENOMICS||Euronext Paris||5.50 (c)||-1.61%||11 496|